Financial Performance - In the first half of 2024, the company achieved operating revenue of 433.66 million CNY, a year-on-year increase of 3.55% [3] - The net profit attributable to shareholders was 122.01 million CNY, reflecting a year-on-year growth of 26.74% [3] - As of June 30, 2024, total assets amounted to 2.48 billion CNY, up 12.16% year-on-year, while net assets attributable to shareholders reached 2.17 billion CNY, increasing by 13.88% [3] Product Sales - The sales revenue for the main products in the first half of 2024 included: - Likujun tablets: 308.28 million CNY - Nigulol tablets: 65.82 million CNY - Yupingfeng capsules: 20.16 million CNY - Other products: 39.40 million CNY [3] - The sales of Nigulol tablets grew by 90.03% year-on-year, indicating effective promotion and market acceptance [4] Market Position and Product Advantages - Nigulol tablets are positioned as a first-class compound antihypertensive drug, particularly effective for patients with mild to moderate primary hypertension and elevated heart rates [4] - The product has shown significant advantages in clinical settings, with a large market potential due to the prevalence of hypertension combined with high heart rates [4] - Likujun tablets are widely used across various medical departments, maintaining a leading market share in the field of leukocyte elevation drugs [5] Research and Development - The company is advancing its new antidepressant JJH201501, which is currently in Phase III clinical trials, showing promising results in extending drug half-life and improving efficacy [6] - The new anti-tumor drug JJH201601 is undergoing clinical trials, demonstrating superior efficacy compared to existing treatments in preclinical models [6] - The company has developed a deuterated drug technology platform, enhancing drug safety and efficacy while reducing dosage requirements [7] Investor Relations - The company is committed to regular profit distribution, with a mid-term dividend plan under consideration for 2024, based on operational performance [6] - In the first quarter of 2024, the company distributed cash dividends totaling 51.10 million CNY [6]

一、基本信息 近日，江苏吉贝尔药业股份有限公司（以下简称"公司"）收到国家药品监 督管理局签发的《化学原料药上市申请批准通知书》，现将相关情况公告如下： 证券代码：688566 证券简称：吉贝尔 公告编号：2024-050 江苏吉贝尔药业股份有限公司 自愿披露关于收到化学原料药上市申请批准 通知书的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 1、登记号：Y20220001207 二、药品的相关情况 盐酸洛美沙星，是一种喹诺酮类抗菌药，临床主要用于治疗各种革兰氏阳性 菌和阴性菌引起的急、慢性感染性疾病，是公司产品盐酸洛美沙星滴眼液的主要 原料。公司产品盐酸洛美沙星滴眼液主要用于治疗急、慢性细菌性结膜炎、睑缘 1 2、化学原料药名称：通用名称：盐酸洛美沙星；英文名/拉丁名：Lomefloxacin Hydrochloride 3、化学原料药注册标准编号：YBY70752024 4、包装规格：3kg/桶 5、申请事项：境内生产化学原料药上市申请 6、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合 ...

二、监事会会议审议情况 经与会监事认真审议，以投票表决方式审议通过以下议案： （一）审议通过《公司 2024 年半年度报告及摘要》 证券代码：688566 证券简称：吉贝尔 公告编号：2024-043 江苏吉贝尔药业股份有限公司 第四届监事会第十次会议决议公告 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 江苏吉贝尔药业股份有限公司（以下简称"公司"）第四届监事会第十次会 议（以下简称"会议"）于 2024 年 8 月 16 日以书面方式发出通知，于 2024 年 8 月 29 日在公司会议室召开。会议应参加表决监事 3 名，实际参加表决监事 3 名， 会议由监事会主席王正先生主持，符合《中华人民共和国公司法》（以下简称"《公 司法》"）及《江苏吉贝尔药业股份有限公司章程》（以下简称"《公司章程》"）的 有关规定，会议合法有效。 根据《公司法》《中华人民共和国证券法》《公开发行证券的公司信息披露内 容与格式准则第 3 号——半年度报告的内容与格式》《上海证券交易所科创板股 票上市规则》等相关法律、法 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, with a total revenue of RMB 500 million, representing a 25% year-over-year growth[1]. - The company's revenue for the first half of 2024 reached ¥433,661,702.66, representing a 3.55% increase compared to ¥418,811,759.66 in the same period last year[20]. - The net profit attributable to shareholders increased by 26.74% to ¥122,005,971.06 from ¥96,263,228.12 year-on-year[20]. - The net cash flow from operating activities rose by 19.76% to ¥131,187,342.50 compared to ¥109,542,754.94 in the previous year[20]. - The gross profit margin improved to 60%, up from 55% in the previous year, indicating better cost management[1]. - The company's total assets at the end of the reporting period were ¥2,478,277,716.59, a 12.16% increase from ¥2,209,668,213.23 at the end of the previous year[20]. - The basic earnings per share increased by 27.45% to ¥0.65 from ¥0.51 in the same period last year[21]. Research and Development - The company has allocated RMB 100 million for research and development in the upcoming year, focusing on advanced drug delivery systems[1]. - The company's R&D expenditure accounted for 8.15% of its revenue, up from 6.83% in the previous year, indicating a focus on innovation[21]. - Total R&D investment increased by 23.57% year-on-year, amounting to ¥35,340,409.17, with a significant increase in the proportion of capitalized R&D expenses[77]. - The number of R&D personnel has increased to 107, representing 8.26% of the total workforce, up from 6.51% in the previous year[86]. - The company has established a comprehensive new drug research and development system, focusing on patient needs and clinical value, supported by a professional R&D team and various innovative drug development technologies[61]. Product Development and Pipeline - New product development includes the launch of two innovative drug formulations expected to enter the market by Q4 2024[1]. - The company is engaged in the development of innovative drugs targeting depression, tumors, and gastric diseases, expanding its therapeutic areas[25]. - The company is advancing its new antidepressant drug JJH201501, currently in Phase III clinical trials, which shows promising pharmacokinetic properties[38]. - The anti-tumor drug JJH201601, developed using liposome technology, has shown superior anti-tumor effects in preclinical models compared to imported drugs, and is currently undergoing Phase I clinical trials[38]. - The company is also developing products for treating gastric acid-related issues, cholecystitis, and diabetes, expanding its therapeutic portfolio[39]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[1]. - The company has established a comprehensive marketing network covering major regions in China, enhancing its market reach[90]. - The company plans to increase its sales force by 20% to enhance customer engagement and support[1]. - The sales strategy combines academic promotion with pharmaceutical distributors, optimizing marketing strategies to enhance product sales to hospitals and pharmacies[65]. Corporate Governance and Compliance - The company has appointed three new independent directors, effective from May 20, 2024, following the resignation of three independent directors who served their maximum term of six years[123]. - The company has committed to ensuring the authenticity and completeness of its prospectus and will compensate investors for any losses due to false statements or omissions[175]. - The company has established measures to prevent and reduce related party transactions to protect the rights of minority shareholders[178]. - The company has not reported any non-operating fund occupation or guarantee violations during the reporting period[190]. Environmental Responsibility - Environmental protection investments during the reporting period amounted to 2.34251 million yuan[130]. - The company achieved wastewater discharge compliance with maximum concentrations of key pollutants such as ammonia nitrogen at 1.486 mg/L, well below the limit of 35 mg/L[131]. - The company has implemented carbon reduction measures, successfully reducing carbon emissions through source control and energy-efficient equipment[138]. - The company has established dedicated wastewater treatment and exhaust gas processing facilities, which have been operating normally without any significant environmental issues[132]. Future Outlook - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 20% to 30%[1]. - The company is focusing on expanding its product pipeline with new anti-depressant drugs, with an investment of 1,900 million yuan planned[200]. - The company anticipates completing the Phase III clinical trials for JJH201601 by the end of 2028[200]. - The company is committed to improving operational management and internal controls to enhance operational efficiency and profitability[171].

证券代码：688566 证券简称：吉贝尔 公告编号：2024-045 江苏吉贝尔药业股份有限公司 关于使用募集资金置换预先投入募投项目 自筹资金的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 江苏吉贝尔药业股份有限公司（以下简称"公司"）拟使用募集资金人 民币 14,196,956.84 元置换预先投入募集资金投资项目（简称"募投项目"） 的自筹资金，符合募集资金到账后 6 个月内进行置换的规定。 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意江苏吉贝尔药业股份有限公 司向特定对象发行股票注册的批复》（证监许可〔2024〕843 号），公司以简易程 序向特定对象发行股票 7,446,889 股，每股面值 1.00 元，每股发行价格为 26.61 元，募集资金总额为人民币 198,161,716.29 元，扣除各项发行费用人民币 9,687,596.06 元（不含税），募集资金净额为人民币 188,474,120.23 元。信永中和 会计师事务所（特殊普通合伙）对公司本次发行新股的资金 ...

江苏吉贝尔药业股份有限公司独立董事 关于第四届董事会第十次会议相关事项的 独立意见 根据《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》 《江苏吉贝尔药业股份有限公司章程》等相关要求,作为江苏吉贝尔药业股份有 限公司(以下简称"公司")的独立董事,我们本着认真负责、实事求是的态度, 对公司第四届董事会第十次会议相关事项进行了认真的了解和查验并发表如下 独立意见: 三、《关于调整 2021 年限制性股票激励计划限制性股票授予价格的议 案》的独立意见 我们认为:公司本次对 2021 年限制性股票激励计划限制性股票授予价格的 调整符合《上市公司股权激励管理办法》及《江苏吉贝尔药业股份有限公司 2021 年限制性股票激励计划(草案)》中关于授予价格调整的规定,本次调整事项在 公司 2021 年第一次临时股东大会授权董事会决策的事项范围内,且履行了必要 的审批程序,本次授予价格调整合法、有效,表决程序符合《中华人民共和国公 司法》《中华人民共和国证券法》等有关法律、法规和《公司章程》的有关规定。 我们同意公司本次对 2021 年限制性股票激励计划限制性股票授予价格进行调整, 并同意本激励计划第三个归属期 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2024-044 江苏吉贝尔药业股份有限公司 2024 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国证券法》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《江 苏吉贝尔药业股份有限公司募集资金使用管理制度》及相关格式指引的规定， 江苏吉贝尔药业股份有限公司（以下简称"公司"）董事会对公司 2024 年半 年度（以下简称"报告期"）募集资金存放与实际使用情况专项说明如下： 一、募集资金基本情况 （一）募集资金金额及到位时间 1、公司首次公开发行股票募集资金情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意江苏吉贝 尔药业股份有限公司首次公开发行股票注册的批复》（证监许可〔2020〕614 号） 同意，公司首次公开发行人民币普通股（A 股）4,673.54 万股， ...

江苏吉贝尔药业股份有限公司（以下简称"公司"）监事会根据《中华人民共 和国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证 券法》")、《上市公司股权激励管理办法》《上海证券交易所科创板股票上市规则》 和《公司章程》等有关规定,对《公司 2021年限制性股票激励计划第三个归属 期激励对象归属名单》进行审核，发表核查意见如下: (以下无正文) 《公司 2021 年限制性股票激励计划第三个归属期激励对象归属名单》中记 载的人员为公司董事会审议激励计划时在公司（含子公司，下同）任职的董事、 高级管理人员、核心技术人员以及董事会认为需要激励的其他人员,上述激励对 象均满足《公司法》《证券法》等有关法律法规、规范性法律文件和《公司章程》 《江苏吉贝尔药业股份有限公司 2021 年限制性股票激励计划(草案)》《江苏吉 贝尔药业股份有限公司 2021 年限制性股票激励计划实施考核管理办法》规定的 归属条件,其作为公司 2021 年限制性股票激励计划第三个归属期激励对象归属 的主体资格合法、有效。 综上,监事会同意公司为本次符合归属条件的激励对象办理限制性股票的归 属,上述事项符合相关法律、法规及 ...

国金证券股份有限公司 关于江苏吉贝尔药业股份有限公司 2024 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规 则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法律、 法规的规定，国金证券股份有限公司（以下简称"保荐机构"）作为江苏吉贝尔药 业股份有限公司（以下简称"吉贝尔""公司"）持续督导工作的保荐机构，负责 吉贝尔的持续督导工作，并出具本持续督导跟踪报告。 2024 年半年度，保荐机构和保荐代表人未发现公司存在重大问题。 三、重大风险事项 公司面临的主要风险如下： （一）核心竞争力风险 一、持续督导工作情况 1 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | | 督导上市公司及其董事、监事、高级管理人 员遵守法律、法规、部门规章和上海证券交 | 在本持续督导期间，保荐机构督导 吉贝尔及其董事、监事、高级管理 人员遵守法律、法规、部门规章和 | | 6 | 易所发布的业务规则及其他规范性文件，并 | 上海证券交易所发布的业务规则及 | | | 切实履行其所做出的各项承诺 | 其他规范性文件，切 ...